When the Taboo Becomes Therapeutic
Psilocybin, MDMA, and ketamine—substances long relegated to the margins of medicine—are advancing through clinical trials with growing institutional legitimacy. The ...
When Geography Governs the Body
When the Supreme Court issued its decision in <em>Dobbs v. Jackson Women’s Health Organization</em> in 2022, overturning <em>Roe v. Wade</em> ...
If the Wealthy Live to 120
Longevity science—once confined to academic gerontology and speculative Silicon Valley forums—has entered capital markets and clinical practice with unusual momentum. ...
When Illness Has No Lab Value
Across clinics and corporate offices, a growing number of Americans identify with chronic conditions that resist straightforward measurement: long COVID, ...
When Hormones Become Lifestyle
Testosterone replacement therapy and broader hormone optimization have migrated from endocrinology clinics into subscription platforms, influencer podcasts, and venture-backed telehealth ...
The Bill That Outlives the Illness
In the United States, healthcare affordability and medical debt remain structurally embedded in the delivery system, not aberrations at its ...
When Authority Fractures
Health misinformation has become less a discrete problem than a structural feature of the digital environment. Social platforms distribute medical ...
The Second Brain Goes Viral
The gut-brain axis—once a niche topic in neurogastroenterology and mucosal immunology—is now a staple of TikTok explainers and supplement ...
The Calendar Becomes Capital
The United States fertility rate has declined to historic lows, falling below replacement level for more than a decade. According ...
Hospital Pharmacies: Designing for Zero Errors
Here’s how smart layout and storage choices in hospital pharmacies reduce mix-ups, streamline workflow, and support safer dispensing without adding ...
When the Dose Is a Guess
The opioid crisis in the United States has entered a synthetic phase defined less by prescription volume than by the ...
When Prognosis Becomes Probabilistic
Cancer immunotherapy and mRNA-based oncology platforms have not abolished mortality, but they have unsettled its predictability. Immune checkpoint inhibitors targeting ...
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more